We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu

Metabolic Phenotyping in Humans (MetPhe)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01298375
Recruitment Status : Recruiting
First Posted : February 17, 2011
Last Update Posted : September 19, 2022
Information provided by (Responsible Party):
Maastricht University Medical Center

Brief Summary:
Type 2 diabetes (T2D) is a global burden disease affecting almost 200 million people and is expected to nearly double by 2030 (1). It is imperative that this disease is kept under control, and that we begin to reverse the direction of its incidence. We propose to start by identifying the physiological and molecular aspects of the problem in all spectrums of the disease (ie from insulin sensitive athletes to sedentary lean and obese individuals and further to overt type 2 diabetics), and focus our efforts on examining the differences and identifying the stages of progression for possible targets of future intervention. The proposed study "Metabolic Phenotyping" is novel in its target populations and innovative in its use of state-of-the-art techniques. We hypothesize that the in vivo differences in metabolic flexibility and mitochondrial function between endurance athletes and type 2 diabetics and their lean and obese controls are retained in vitro and will offer a new model in which to study the underlying mechanisms of the progression of T2D.

Condition or disease
Healthy Obesity Type 2 Diabetes Mellitus

Detailed Description:

The aim of the present research proposal is to metabolically phenotype endurance trained athletes, lean and obese sedentary and type 2 diabetic individuals with the following objectives:

  1. assess metabolic flexibility as measured by a euglycemic-hyperinsulinemic clamp
  2. measure in vivo mitochondrial function by MRS of phosphocreatine (PCr) recovery
  3. establish primary myoblast cell lines to correlate with the above in vivo measurements, as well as further explore dietary, pharmacological and genetic manipulations in vitro
  4. quantify intramyocellular lipid (IMCL) and acetylcarnitine in vivo by MRS

Study population:

A total of 132 male participants (18-70 years) will participate in this study. The first group of 33 participants will be lean endurance-trained athletes, the second group will be lean sedentary control participants, the third group will be sedentary type 2 diabetic participants, and the last group of 33 participants will be obese, non-diabetic sedentary control participants. It is preferred to use male participants in order to minimize variation in the measurements by avoiding confounding factors such as hormones.

Main study parameters/endpoints: The main study parameters are differences in metabolic flexibility as measured by euglycemic-hyperinsulinemic clamp, PCr recovery, IMCL and acetylcarnitines as measured by MRS and establishment of primary myoblast cell lines for future use.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 132 participants
Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: Metabolic Characterization of Type 2 Diabetic, Obese, Lean Sedentary and Endurance Trained Individuals in Vivo, ex Vivo and in Vitro
Study Start Date : March 2011
Estimated Primary Completion Date : March 2024
Estimated Study Completion Date : March 2024

Resource links provided by the National Library of Medicine

Primary Outcome Measures :
  1. Euglycemic-hyperinsulinemic clamp for measurement of insulin sensitivity and metabolic flexibility [ Time Frame: 10 hours ]
    After taking fasting blood samples, a primed constant infusion of glucose is initiated. Plasma glucose levels are clamped at ~5 mmol/L by variable co-infusion of 20% glucose. Every 5 minutes, blood is sampled for immediate determination of plasma glucose concentration. Glucose infusion rate is adjusted to obtain plasma glucose levels of ~5 mmol/L (euglycemia). A bolus of insulin is then infused. Before and during steady state, substrate oxidation is measured using an indirect calorimeter, which determines metabolic flexibility.

Secondary Outcome Measures :
  1. Evaluating mitochondrial function through measurement of phosphocreatine (PCr) recovery by phosphorus magnetic resonance spectroscopy (31P-MRS) within the skeletal muscle [ Time Frame: 1.5 hours ]
    The quantification of energy metabolites (Pi, PCr and ATP) in skeletal muscle will be performed in the v. lateralis at rest, during submaximal knee-extension exercise and during recovery. The rate at which PCr concentration is restored after exercise is an excellent in vivo measure of skeletal muscle mitochondrial oxidative capacity.

Biospecimen Retention:   Samples With DNA
DNA, RNA, tissue, primary myoblasts, mitochondria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Human volunteers from the surrounding area

General Inclusion criteria:

  • Male sex
  • Generally healthy with specifically no known cardiovascular disease or gastric ulcers, which can affect the study parameters
  • Stable dietary habits (no weight loss/gain > 3 kg in the last 6 months)

Group 1, type 2 diabetes participants:

  • Ages 40-70 years
  • BMI > 30 kg/m2
  • Non-insulin dependent type 2 diabetes
  • Must be on sulphonylurea (SU)-derivate or metformin therapy for at least six months with a constant dose for at least two months, or on dietary treatment for at least six months
  • Well-controlled diabetes: HbA1c < 8%
  • No diabetes related co-morbidities like cardiovascular diseases, diabetic foot, polyneuropathy, retinopathy

Group 2, obese healthy control participants:

  • Ages 40-70 years
  • BMI > 30 kg/m2
  • A plasma glucose level lower than 6.1 mmol/L
  • No family history of diabetes
  • No medication use
  • Sedentary lifestyle; No participation in any physical activity for at least 2 years

Group 3, endurance trained athletes:

  • Ages 18-35 years
  • BMI < 25 kg/m2
  • No family history of diabetes
  • No medication use
  • VO2max > 55ml/kg/min
  • Active in competitive endurance-exercise activities, 3 times a week for at least 2 years
  • Stable level of training for at least 6 months

Group 4, lean healthy sedentary control participants:

  • Ages 18-35 years
  • BMI < 25 kg/m2
  • No family history of diabetes
  • No medication use
  • VO2max < 55ml/kg/min
  • Plasma glucose < 6.1 mmol/L
  • Sedentary lifestyle; No participation in physical activity for more than 1 hour per week for at least 2 years

General Exclusion criteria:

  • Regular smokers
  • Participation in other studies
  • Female sex
  • Insulin dependent diabetic individuals
  • Participants with diabetes related diseases (diabetic foot, diabetic polyneuropathy, diabetic retinopathy etc.)
  • Use of Thiazolidines (glitazone/rosiglitazone/pioglitazone/troglitazone)
  • Use of anti-coagulants (not thrombocyte-aggregation inhibitors)
  • Aberrant ECG (with signs of ischemia or cardiac failure or arrythmias)
  • Weight gain/loss > 3 kg in the last 6 months
  • HbA1c < 7.8 in type 2 diabetic individuals
  • Contraindications for MRS scans:

    • Electronic implants such as pacemakers or neurostimulator
    • Iron-containing foreign bodies in eyes or brain
    • Some hearing aids and artificial (heart) valves which are contraindicated for MRS
    • Claustrophobia
  • Participants, who do not want to be informed about unexpected medical findings, or do not wish that their physician be informed, cannot participate in the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01298375

Layout table for location contacts
Contact: Madeleen Bosma, M.S. 31433884254 m.bosma@maastrichtuniversity.nl
Contact: Bram Brouwers, B.S. 31433884258 b.brouwers@maastrichtuniversity.nl

Layout table for location information
Maastricht University Recruiting
Maastricht, Limburg, Netherlands, 6200MD
Contact: Madeleen Bosma, M.S.    31433884254    m.bosma@maastrichtuniversity.nl   
Principal Investigator: Lauren M Sparks, PhD         
Principal Investigator: Madeleen Bosma, M.S.         
Sub-Investigator: Vera Schrauwen-Hindeling, PhD         
Sponsors and Collaborators
Maastricht University Medical Center
Layout table for investigator information
Study Director: Patrick Schrauwen, PhD Maastricht University
Principal Investigator: Lauren M Sparks, PhD Maastricht University
Principal Investigator: Madeleen Bosma, M.S. Maastricht University
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Maastricht University Medical Center
ClinicalTrials.gov Identifier: NCT01298375    
Other Study ID Numbers: NL35178.068.11
First Posted: February 17, 2011    Key Record Dates
Last Update Posted: September 19, 2022
Last Verified: September 2022
Keywords provided by Maastricht University Medical Center:
Metabolic flexibility
Mitochondrial function
Human primary myoblasts
Lipid metabolism
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus, Type 2
Diabetes Mellitus
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases